We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Renal outcomes after contrast exposure in patients with diabetes who use sodium–glucose cotransporter 2 inhibitors.
- Authors
Chen, Chih-Wei; Su, Fu-You; Wang, Ping-Ping; Chuang, Ming-Tsang; Lin, Yi-Cheng; Kao, Chih-Chin; Huang, Chun-Yao
- Abstract
Background Contrast-induced nephropathy has become increasingly prevalent as the age and prevalence of comorbidities in the general population have increased. Most cases of contrast-induced nephropathy are reversible; however, some may progress to acute kidney disease, and subsequently, to chronic kidney disease. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are known for their renoprotective effects. However, whether the use of these inhibitors affects the risk of contrast-induced kidney injury remains unclear. Methods Data were collected from the Taipei Medical University Clinical Research Database. We included patients with diabetes who had contrast exposure between 2016 and 2020 because of computed tomography or coronary angiography. The primary outcome was the risk of a major adverse kidney event (MAKE), which encompassed acute kidney disease, chronic kidney disease progression, and the need for renal replacement therapy. Overlap weighting was performed to reduce the effects of potential confounders. Results This study included 12 421 patients, who were divided into two groups: SGLT2i users (n = 920) and nonusers (n = 11 501). The follow-up period after contrast exposure was 6 months. The risk of a MAKE was lower in SGLT2i users than in nonusers (incidence, 36.9 vs. 49.9 per 1000 person-months, respectively; P = .0011). Furthermore, the incidence of acute kidney disease or chronic kidney disease progression was significantly lower in the SGLT2i users than in nonusers. However, no significant between-group difference was noted in the incidence of other MAKEs. Conclusions SGLT2i may be safely used in diabetic patients needing contrast exposure. The risk of a MAKE may be lower in SGLT2i users than in nonusers.
- Subjects
SODIUM-glucose cotransporters; SODIUM-glucose cotransporter 2 inhibitors; CONTRAST induced nephropathy; CHRONIC kidney failure; PEOPLE with diabetes; KIDNEY diseases
- Publication
Postgraduate Medical Journal, 2024, Vol 100, Issue 1181, p142
- ISSN
0032-5473
- Publication type
Article
- DOI
10.1093/postmj/qgad118